Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547175 | 0.89 | GFER (0.54) | GFERALDH1A1MAOBMAOARECQL | |
| SCHEMBL31577196 | 0.85 | MAOB (0.55) | GFERMAOB | |
| SCHEMBL5945697 | 0.83 | KMT2A (0.50) | ALDH1A1LMNAPRMT1 | |
| SCHEMBL73828 | 0.82 | FFAR1 (0.65) | GFERMAOBMAOAFFAR1KEAP1 | |
| SCHEMBL4667379 | 0.82 | CAPN1 (0.52) | CAPN1ALDH1A1LMNAPRMT1FFAR1 | |
| SCHEMBL18586398 | 0.82 | CAPN1 (0.52) | CAPN1ALDH1A1LMNAPRMT1FFAR1 | |
| SCHEMBL154384 | 0.82 | CA2 (0.61) | CAPN1ALDH1A1LMNAPRMT1RECQL | |
| Hydrochloric Acid SCHEMBL3128046 | 0.80 | FFAR1 (0.63) | GFERMAOBMAOAFFAR1KEAP1 | |
| SCHEMBL5498931 | 0.80 | GFER (0.54) | GFERALDH1A1MAOBMAOARECQL | |
| SCHEMBL1404834 | 0.80 | ALDH1A1 (0.63) | GFERALDH1A1LMNAMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | claimed |
| CN-114539158-A | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2022-05-27 | — | — | CN | claimed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| CN-86105641-A | The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide | — | 1987-04-01 | — | — | CN | claimed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-5464864-A | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
| EP-0591280-A1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000086-A1 | USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-01-07 | — | — | WO | disclosed |
| CN-1011784-B | Process for preparing antiallergic and antimuscotromospasm agents N-benzhydryldiazacycloalkylalkyl anilides | RECKORDATY CHEMICALS CORP (CH) | 1991-02-27 | — | — | CN | disclosed |
| US-4675319-A | Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use | RECORDATI S. A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1987-06-23 | — | — | US | disclosed |
| CN-86105641-A | The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide | — | 1987-04-01 | — | — | CN | disclosed |
| US-4261883-A | OLIGOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CAPN1 3529/4885ALDH1A1 1152/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CAPN1 3529/4885ALDH1A1 1152/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CAPN1 3529/4885ALDH1A1 1152/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CAPN1 3529/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.